Literature DB >> 21447832

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

Jürgen Thiele1, Hans Michael Kvasnicka, Leonhard Müllauer, Veronika Buxhofer-Ausch, Bettina Gisslinger, Heinz Gisslinger.   

Abstract

Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary myelofi-brosis (PMF) presenting with thrombocythemia. To investigate the impact and reproducibility of bone marrow (BM) morphology according to the World Health Organization classification, 295 patients with the presumptive clinical diagnosis of either ET or early PMF were studied. Data of this cohort (Vienna group) were compared with 732 corresponding patients (Cologne group). Evaluating blindly (only age and gender known) BM specimens, the 2 groups of pathologists achieved an overall consensus of 78% regarding the total series and 88% concerning the discrimination between ET versus PMF. In 126 ET and 81 early PMF patients without pretreatment and complete documentation, a 90% concordance with the independently established clinical diagnosis was found. In 12 patients, overlapping of histopathology and some clinical findings between ET and polycythemia vera occurred. Contrasting ET, early PMF showed significant differences of presenting hematologic data and an unfavorable prognosis (estimated mean survival, 14 vs 21 years). Comparison of clinical and survival data of the Vienna cohort with the historical Cologne series revealed an overall congruence. This study highlights the impact of BM morphology for the differentiation between true vs false ET.

Entities:  

Mesh:

Year:  2011        PMID: 21447832     DOI: 10.1182/blood-2010-07-293761

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.

Authors:  Jürgen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Vito Franco; Emanuela Boveri; Umberto Gianelli; Heinz Gisslinger; Francesco Passamonti; Ayalew Tefferi; Tiziano Barbui
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

2.  Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm.

Authors:  Laura Laine Herborg; Line Nederby; Eigil Kjeldsen; Kirsten Grønbæk; Peter Hokland; Maria Hansen; Marcus Celik Hansen; Anne Stidsholt Roug
Journal:  Leuk Res Rep       Date:  2013-07-04

Review 3.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 4.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

5.  Equivalence of BCSH and WHO diagnostic criteria for ET.

Authors:  C N Harrison; M F McMullin; A R Green; A J Mead
Journal:  Leukemia       Date:  2016-11-29       Impact factor: 11.528

Review 6.  [WHO classification of myeloid neoplasms].

Authors:  C Wickenhauser
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

7.  Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masafumi Ito; Masaaki Sekine; Yoko Kubuki; Tomonori Hidaka; Keiichi Akizuki; Yuki Tahira; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Haruko Shimoda; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-07-09       Impact factor: 2.490

Review 8.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

9.  Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

Authors:  Cecilia Arana Yi; Ghayathri Jeyakumar; Pedro Medina; Jorge Cortes; Sherry Pierce; Carlos Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-11-13       Impact factor: 3.156

Review 10.  Advances in myelofibrosis: a clinical case approach.

Authors:  John O Mascarenhas; Attilio Orazi; Kapil N Bhalla; Richard E Champlin; Claire Harrison; Ronald Hoffman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.